Stocktoria
XOMA Royalty Corp XOMA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1986-06-06
XOMA Royalty Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 21.8% | -140.3% | -879.5% | -288.9% | 45.9% |
| Net margin | 60.8% | -48.5% | -858.2% | -283.8% | 41.4% |
| FCF margin | — | -48.3% | -382.0% | — | — |
| Return on assets | 11.6% | -6.2% | -17.4% | -12.2% | 9.5% |
| Return on equity | 37.8% | -22.3% | -46.0% | -13.8% | 11.1% |
| Debt / equity | 1.15× | 1.73× | 1.34× | 0.00× | — |
| Current ratio | 3.37 | 5.15 | 8.68 | 8.98 | 7.48 |
| Revenue growth | 83.1% | 498.7% | -21.1% | -84.2% | 29.9% |
Source: SEC EDGAR filings · CIK 0000791908 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.